Support Alert

Drug safety update: Adrenaline auto-injectors: reminder for prescribers to support safe and effective use

Emerade 300 and 500 microgram adrenaline auto-injectors have been re-supplied to the market following the implementation of corrective actions – patients and their caregivers should be provided with training and advice specific to their prescribed adrenaline auto-injector. Follow the advice in the Summary of Product Characteristics for dosing considerations and continue to reiterate to patients the importance of always carrying 2 in-date adrenaline auto-injectors with them at all times.

Further details of the drug safety alert and advice for healthcare professionals can be found on the MHRA website